Publication | Closed Access

Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study

Hematological MalignancyHigher-risk Myelodysplastic SyndromesMedicineMixed-phenotype Acute LeukemiaImmunologyHematologyChronic Myelomonocytic LeukaemiaPharmacotherapyOral DecitabineOncologyMyeloid Neoplasia